Factor XIII in the treatment of hemophilia A

New England Journal of Medicine

Volumn 366, Issue 3, 2012, Pages 281-283

  Rea, Catherine J ^a   Foley, Jonathan H ^b   Sørensen, Benny ^c  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF VERMONT   (United States)

^c ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 13; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 CONCENTRATE; RECOMBINANT BLOOD CLOTTING FACTOR 8; THROMBIN; THROMBOPLASTIN; TISSUE PLASMINOGEN ACTIVATOR;

BLEEDING; BLOOD CLOT; DRUG HALF LIFE; FIBRIN FORMATION; HEMOPHILIA A; HUMAN; LETTER; PRIORITY JOURNAL; THROMBOCYTE POOR PLASMA; TURBIDITY;

EID: 84856142615     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1113270     Document Type: Letter

References (4)

1. Blombäck B, Carlsson K, Fatah K, Hessel B, Procyk R. Fibrin in human plasma: gel architectures governed by rate and nature of fibrinogen activation. Thromb Res 1994;75:521-38. (Pubitemid 24267336)
2. Brummel-Ziedins KE, Branda RF, Butenas S, Mann KG. Discordant fibrin formation in hemophilia. J Thromb Haemost 2009;7:825-32.
3. Naski MC, Lorand L, Shafer JA. Characterization of the kinetic pathway for fibrin promotion of alpha-thrombin-catalyzed activation of plasma factor XIII. Biochemistry 1991;30:934-41.
4. Visich JE, Zuckerman LA, Butine MD, et al. Safety and pharmacokinetics of recombinant factor XIII in healthy volunteers: a randomized, placebo-controlled, double-blind, multi-dose study. Thromb Haemost 2005;94:802-7. (Pubitemid 41489241)